Abnormal sperm production and reduced fertility have been reported in transgenic male mice lacking the ␣-subtype of the estrogen receptor (ER)␣ or aromatase. The aim of this study was to investigate the role of estrogen in male reproductive function, by determining the effect of estradiol on testicular function in hypogonadal (hpg) mice congenitally lacking gonadotropin; and thus, sex steroid production. hpg mice were treated, at 2-3 months of age, with slow-release estradiol implants, which achieved circulating estradiol concentrations of approximately 40 pg/ml. Treatment for 35 days reliably induced a 4-to 6-fold increase in testicular weight, compared with the vestigial testes in the untreated or cholesterol-treated controls. The degree of testicular growth after 35 days was similar to that in hpg mice receiving an intrahypothalamic graft of preoptic area tissue taken from neonatal mice on the day of birth, a procedure known to induce testicular development in hpg mice by activation of the pituitary gland. Histological analysis revealed that the testes contained elongated spermatids after 35 days of estradiol treatment, whereas germ cell development never progressed beyond the pachytene stage in control hpg mice. Treatment for 70 days induced full qualitatively normal spermatogenesis in hpg mice. Testis weight increased 5-fold, reflecting a 5-fold increase in total seminiferous tubule volume and a 4-to 5-fold increase in the total volume of the seminiferous epithelium. In all experiments, spermatogenesis proceeded in the absence of measurable androgen concentrations, but circulating FSH concentrations were slightly (but significantly) elevated, relative to cholesterol-treated control hpg mice. This stimulatory action of estradiol on FSH secretion was unexpected, particularly because identical estradiol treatments significantly decreased serum FSH levels in wild-type littermates. These results indicate that estrogens may play a role in spermatogenesis, via stimulatory effects on FSH secretion. An alternative or complementary explanation, given the recent identification of estrogen receptors (ER␣ and ER␤) and aromatase within various cell types in the testis, is that estrogens exert paracrine actions within the testis to promote spermatogenesis. The identification of effects of estradiol on testicular function provides a conceptual basis to reexamine the speculative link between increased exposure to environmental estrogens and reduced fertility in man. (Endocrinology 141:
normal spermatogenesis in hpg mice. Testis weight increased 5-fold, reflecting a 5-fold increase in total seminiferous tubule volume and a 4-to 5-fold increase in the total volume of the seminiferous epithelium. In all experiments, spermatogenesis proceeded in the absence of measurable androgen concentrations, but circulating FSH concentrations were slightly (but significantly) elevated, relative to cholesterol-treated control hpg mice. This stimulatory action of estradiol on FSH secretion was unexpected, particularly because identical estradiol treatments significantly decreased serum FSH levels in wild-type littermates. These results indicate that estrogens may play a role in spermatogenesis, via stimulatory effects on FSH secretion. An alternative or complementary explanation, given the recent identification of estrogen receptors (ER␣ and ER␤) and aromatase within various cell types in the testis, is that estrogens exert paracrine actions within the testis to promote spermatogenesis. The identification of effects of estradiol on testicular function provides a conceptual basis to reexamine the speculative link between increased exposure to environmental estrogens and reduced fertility in man. (Endocrinology 141: [2861] [2862] [2863] [2864] [2865] [2866] [2867] [2868] [2869] 2000) C RITICAL ANALYSIS OF the suggested link, between exposure to xenoestrogens during early development and reduced fertility in later life, has been limited by the lack of understanding of the role of estrogens in male reproductive function (see Refs. 1 and 2 for review). Estrogens, derived either from local aromatization of androgens or produced by the testis, can exert feedback effects on the neuroendocrine components of the male reproductive axis, but recent evidence suggests that estrogen may also exert paracrine actions within the testis itself (see Ref. 3 for review). Transgenic male mice lacking the estrogen receptor (ER)␣ have low sperm numbers and defective sperm function resulting in greatly decreased fertility (4, 5) . This reduced sperm production is thought to be a consequence of impaired fluid resorption within the efferent ducts of the testis (6, 7) , because ER␣ immunoreactivity has been detected in the efferent ducts of the rat and developing marmoset (8) . The identification of ER␣ immunoreactivity within Leydig cells and of a second estrogen receptor (ER␤) within several cell types in the rat testis, including germ cells and Sertoli cells (9, 10) , raises the likelihood that estrogens have additional functions within the testis. Unraveling these physiological actions is particularly important, given the widespread interest in the association between environmental estrogens and fertility in the male (2, 11, 12) and recent demonstrations that various xenoestrogens can disrupt testicular development (13, 14) .
The hypogonadal (hpg) mouse has been widely used to investigate the hormonal regulation of testicular function because it lacks the ability to produce mature GnRH decapeptide (15, 16) . As a result, these mice are hypogonadotrophic, with vestigial testes, and have provided a unique model to investigate the effects of gonadotropins and androgens in the testis (17) (18) (19) , though their unusual developmental history (for example, the lack of androgenization in the neonatal period) may need to be considered when extrapolating findings from this strain to other species. The approach of the current study was to treat hpg mice with estradiol and to assess the effects on endocrine function and development of the testes, epididymides, and seminal vesicles. The effects of chronic estradiol treatment were com-pared with the effects of a qualitatively normal gonadotropic drive induced by grafts of wild-type preoptic area brain tissue, containing GnRH neurons, into the hypothalamus of hpg mice, a procedure previously demonstrated to induce testicular development and spermatogenesis by activation of the pituitary gland (20, 21) .
Materials and Methods Animals
All procedures were licensed under the Animals (Scientific Procedures) Act of 1986 and were conducted in accordance with the University of Cambridge Scientific Procedures on Animals Code of Practice. Studies were carried out in C3H hpg mice (Mus musculus), 2-3 months old at the start of the experiment, supplied from a breeding colony at the Department of Anatomy, University of Cambridge, originally derived from stock purchased from Jackson ImmunoResearch Laboratories, Inc. (Bar Harbor, ME). After steroid or graft treatments, mice were individually housed with food and lab chow available ad libitum and were maintained on a 12-h light, 12-h dark photoperiod. Genotype of all individuals was ascertained using a PCR analysis of DNA extracted from ear punches, as described by Lang (22) .
Steroid treatments and hormone assays
Implants were made by packing 10 mm crystalline cholesterol (Sigma Chemical Co., Poole, UK), or 17␤-estradiol (Sigma) mixed 1:50 (2%) or 1:10 (10%), by weight with cholesterol, or testosterone (Sigma) into Silastic tubing (1.59-mm id, 3.18-mm od; Osteotec, Christchurch, Dorset, UK) plugged at either end with silicone medical adhesive (Osteotec). After the adhesive had been allowed to cure for at least 24 h at room temperature, the implants were washed three times in 70% ethanol. The implants were incubated for 24 h in 0.01m PBS, pH7.4, before implantation, so that release rates would be stabilized by the time the implants were placed under the skin (23) . Mice were anesthetized with halothane, and the Silastic implants were placed into a sc pocket on their flank. At the end of treatment periods, blood samples were collected by cardiac puncture, under terminal anesthesia (sodium pentobarbitone, ip), and allowed to clot at room temperature. After centrifugation, serum was harvested and stored at Ϫ20 C until required for assay. All estradiol concentrations were measured in a single assay after extraction of 150 l serum in hexane:ether using a commercially available ELISA kit (Fenzia: Orion Diagnostica, Finland). The limit of detection was 15 pg/ml, and the intraassay coefficient of variation (cv), based on all duplicates, was 8.7%. Testosterone concentrations were measured using an ELISA, after extraction of 150 l serum in hexane:ether, exactly as previously described (24) . The limits of detection were 0.03-0.05 ng/ml, the mean intraassay cv was 8.1%, and the interassay cv for an adult male wild-type pool run in all assays (n ϭ 3) was 7.0%. FSH concentrations were measured in a single assay using a mouse FSH kit from Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK); the limit of detection was 1.6 ng/ml, and the intraassay cv was 12.5%.
Morphometric procedures
After blood collection, 3 or 4 mice from each group were perfused, via the left ventricle of the heart, with 0.01 m phosphate-buffered 0.9% saline, pH 7.2, followed by 4% paraformaldehyde, for a minimum of 5 min or until the fixed testes became hardened. The reproductive tracts were excised, trimmed of fat and connective tissue, and weighed. Epididymides and seminal vesicles were processed for paraffin histology, and 7-m sections through their long axes were stained with hematoxylin-eosin for light microscope analysis. Each fixed testis was cut in half in the midtransverse plane, and each piece was processed for paraffin histology, with orientation in the block, to yield cross-sections of the testis. Sections were cut at 7 m and stained with hematoxylin-eosin. Point-counting methods were used to measure volume density (V v ) of seminiferous tubules (or cords), seminiferous epithelium, and tubular lumen, using a ϫ25 objective and a ϫ10 eyepiece containing a square lattice with 121 (11 ϫ 11) intersections as test points. The number of so-called hits, on the above components, was counted with no overlap or gap in each area sampled. The whole stained section from each specimen was analyzed with 5 to 10 areas sampled randomly, depending on the size of the testis. V v of testicular components were obtained by dividing the number of hits on each structure by the total number of points superimposed over the tissue. Volume percentage was calculated by multiplying V v by 100. Volumes of components per testis were determined by multiplying V v by whole testicular fixed volume, the latter being numerically equal to fixed testicular weight because the specific gravity of testicular tissue is very close to 1.0. The volume density and total volume of Sertoli cell nuclei per testis were determined by point counting, as above, using a ϫ40 oil-immersion objective.
The diameters of seminiferous tubules (or cords) were measured across the minor axis (n ϭ 20 per testis) using an eyepiece micrometer calibrated with a stage micrometer using a ϫ25 objective and ϫ10 eyepiece. Total length (L) of the seminiferous tubules per testis was calculated by the equation L ϭ V ST /r 2 , where V ST is the total volume of seminiferous tubules per testis (measured above) and r is the average radius of the tubule.
Bioassay
Female C3H mice were genotyped using a PCR analysis of DNA extracted from ear punches, as described by Lang (22) ; and homozygote hpg individuals received 2% estradiol implants, as described above for males, or received implants containing 10% crystalline estradiol-17␤ in cholesterol, or cholesterol alone as a control. Blood samples were collected for estradiol assay, as described above, and the reproductive tract was dissected and weighed after 12 days of treatment.
Hypothalamic grafts
Postnatal day 0 pups from wild-type C3H stock were killed by decapitation, and the brains were rapidly removed and placed on their dorsal surface in a sterile Petri dish. A block was excised with an iridectomy knife, with lateral cuts approximately 0.5 mm either side of midline, a caudal cut through the rostral part of the tuber cinareum, a rostral cut approximately 1 mm in front of this caudal cut, and a cut approximately 0.5-mm deep to the ventral surface. The tissue was gently minced with the iridectomy knife and drawn into the needle of a 5-l Hamilton syringe. Male hpg mice were anesthetized with xylazine/ rompun and placed in a Kopf stereotaxic frame with incisor bar level with the ear bars. A small burr hole was drilled through the skull at bregma, and the needle containing the graft was lowered 0.60 cm below the dural surface on midline. The graft was gently ejected into the third ventricle, and hemorrhage from the midsaggital sinus was stemmed with gelfoam and compression.
Statistical analysis
Organ weight data from each experiment were analyzed by factorial ANOVA followed by post hoc Dunnett's t tests. Hormonal data were analyzed by Kruskal-Wallis tests when concentrations for control groups fell below the limit of detection of the assay. Tests were carried out on a Macintosh G3 computer using Statview software (Abacus Concepts, Berkeley, CA). For all tests, significance was set at P Ͻ 0.05.
Results

Exp I
The aim of the initial experiment was to determine whether estradiol treatment affected testicular development in hpg mice. Hpg mice were treated, for 35 days, with slowrelease sc implants containing 2% 17␤-estradiol in cholesterol. The main control group received implants containing cholesterol only, for 35 days. Additional groups of agematched wild-type or hpg mice with no implants, and of grafted hpg mice (see above), were also included as interpretative controls. Testicular weight was uniformly low in cholesterol-treated hpg males (Fig. 1 , Table 1 ) and in untreated hpg males (Fig. 1) . The estradiol-treated group showed a 4-fold increase (P Ͻ 0.001) in testicular weight, compared with untreated or cholesterol-treated control hpg mice ( Fig. 1 , Table 1 ). The degree of testicular growth was similar to that in hpg mice receiving an intrahypothalamic graft of preoptic area tissue taken from neonatal mice on the day of birth (Fig. 1 ), but testis weight in estradiol-treated or grafted hpg mice was significantly less than in wild-type littermates of a similar age (Fig. 1) . Despite the increase in testicular weight, circulating androgen concentrations were undetectable in the hpg mice treated with estradiol ( Fig. 1,  lower panel) , whereas a significant increase (P Ͻ 0.01) in circulating androgen occurred when testicular growth was driven by the hypothalamic graft (Fig. 1, lower) . Estradiol treatment also increased by 4-fold the wet weight of the epididymides (P Ͻ 0.05; Table 1 ), but it decreased body weight (P Ͻ 0.05; Table 1 ) and decreased the weight of the epididymal fat pad (P Ͻ 0.005; Table 1 ), a marker of abdominal fat reserves. Thus, the growth of the testis and epididymis in estrogen-treated hpg mice was not a reflection of increased growth overall; the estradiol treatment was clearly catabolic.
Exp II
A second study was conducted with the aims of examining the histology of the testis and epididymis and to determine whether the estradiol treatments were producing hormone concentrations within the normal physiological range. Estradiol treatment, for 35 days, increased testes weight by 6-fold, compared with cholesterol-treated hpg mice (Fig. 1 , top right), and as observed previously, serum androgen concentrations remained below the limit of detection (Fig. 1 , bottom right). As before, estradiol induced a reduction in body weight (cholesterol, 34.5 Ϯ 3.6 g vs. 2% estradiol, 27.7 Ϯ 1.3 g).
Testes from cholesterol-treated hpg mice had a very immature histology, consisting of seminiferous cords or narrow tubules with small lumina (e.g. Exp III, see Fig. 4a ). Sertoli cells often were clustered in the center of the cords. Spermatids were absent, and primary spermatocyte development was arrested at midpachytene. The cholesterol-treated hpg mice also had shrunken epididymal tubules with very small lumina (e.g. Exp III, see Fig. 4g ). Spermatogenesis was clearly more advanced in the estradiol-treated hpg mice, all animals exhibiting variable (but low) numbers of round and elongating spermatids; although the abundance of the latter seemed much reduced, compared with wild-type testes. Estradiol caused a marked expansion of the epididymal lumen, suggestive of increased fluid content, though the gross size of the epididymis was still less than that found in wild-type males.
Serum estradiol concentrations in male and female hpg mice treated with cholesterol ( Fig. 2, upper) , were undetectable, whereas the 2% and 10% estradiol implants dosedependently increased circulating estradiol concentrations (Fig. 2, upper) . The range of values in hpg mice treated with the 2% implants was 25-54 pg/ml, below those (100 -200 pg/ml) reported for proestrous female mice with a more sensitive RIA (25) . In the female hpg mice, 12 days of treatment with the sc implants produced increases in uterine weight comparable with nonpregnant age-matched wildtype littermates (Fig. 2, lower) .
Serum FSH concentrations in the male hpg mice treated with cholesterol (Fig. 3, left) were undetectable or close to the limit of detection, whereas FSH levels were detectable in all hpg mice treated with 2% estradiol implants. Levels were significantly elevated (P Ͻ 0.05) in the estradiol-treated hpg mice, compared with the cholesterol-treated hpg mice, but were 4-fold lower than in age-matched male wild-type littermates (Fig. 3) sampled as a positive control for the assay.
FIG. 1. Exp I: (top left)
Paired testes weights and (bottom left) serum testosterone concentrations in 2-to 3-month-old hpg mice treated for 35 days with cholesterol implants (CHOL) or 2% 17␤-estradiol implants (E), no treatment (Ϫ), hypothalamic grafts (graft) or in agematched wild-type littermates (ϩ/ϩ). Values are group mean Ϯ SE, n ϭ 4 per group. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001 vs. cholesterol-treated control group. Exp II: (top right) paired testes weights and (bottom right) serum testosterone concentrations in a second experiment: hpg mice were treated for 35 days with CHOL or 2% E; values are group mean Ϯ SE, n ϭ 4 per group. Note that, in both experiments, estradiol treatment increased testicular weight, but serum testosterone concentrations remained undetectable, whereas growth driven by hypothalamic grafts was accompanied by an increase in circulating testosterone. Serum FSH concentrations were also measured in blood samples collected from a pilot experiment in which adult wildtype C3H mice were treated for 12 days with sc implants containing cholesterol, 2% estradiol, or 10% estradiol (Fig. 3,  right) . Both estradiol treatments significantly (P Ͻ 0.005) reduced serum FSH levels, relative to the cholesterol-treated mice (Fig. 3, right) .
Exp III
Because spermatogenesis in the mice treated with estradiol for 35 days was qualitatively and quantitatively incomplete, compared with normal mice, a third study was conducted to investigate whether complete spermatogenesis could be induced in hpg mice by a longer period of treatment, or a greater dose of estradiol, or by additional exposure to testosterone. Three groups of hpg mice received implants of cholesterol, or 2% or 10% estradiol for 70 days; and two subgroups, treated with cholesterol or 2% estradiol, also received Silastic implants containing 100% testosterone for the final 35 days of the experiment. Estradiol treatments for 70 days were sufficient without additional androgen supplementation to induce full qualitatively normal spermatogenesis ( Fig. 4; c, d , and i), comparable with that seen in wild-type controls (Fig. 4, b  and h ). The histological appearance of the testes (Fig. 4, c  and d ) and wet weights of the testes (Fig. 5, top) , epididymides (Fig. 5, second from bottom panel) , and seminal vesicles (Fig. 5, bottom) were similar in the groups treated with either 2 or 10% estradiol. Serum testosterone concentrations remained below the limit of detection in the hpg mice treated with 2 or 10% estradiol (Fig. 5, second from top) , but circulating FSH concentrations were significantly elevated by this treatment (Fig. 5, middle) , albeit not to the levels seen in male wild-type mice (Fig. 5, middle) .
Morphometric analysis of paraffin sections stained with hematoxylin and eosin revealed that estradiol treatment for 70 days induced a 5-fold increase in total seminiferous tubule volume (Table 2) , which reflected a 4-to 5-fold increase in the total volume of the seminiferous epithelium ( Table 2 ). The total tubule length per testis did not differ significantly between any of the experimental groups (Table 2) . Testosterone supplementation produced no further increase in the total volume of seminiferous tubules or of the seminiferous epithelium ( Table 2 ), confirming that estradiol treatment alone increased the spermatogenic activity of the seminiferous tubules. Both estradiol doses resulted in an abundance of mature spermatozoa in the epididymis (Fig. 4i) . The estradiol treatments significantly increased the total volume of Sertoli cell nuclei in the testis (Table 2) and, by inference, the number of Sertoli cells present (though, after estradiol treatment, the total volume of Sertoli cell nuclei still only reached about one
FIG. 2.
Top, Serum estradiol concentrations in 2-month-old female hpg mice treated for 12 days with CHOL, 2% 17␤-estradiol implants (2%E), 10% 17␤-estradiol implants (10% E) or in males receiving implants for 35 days in Exp II. Values are group mean Ϯ SE, n ϭ 3-4 per group. Bottom, Uterus weights in the hpg females receiving cholesterol or estradiol implants for 12 days (see top) or in untreated age-matched wild-type littermates (ϩ/ϩ).
FIG. 3.
Left, Exp II, Serum FSH concentrations in male hpg mice treated for 35 days with cholesterol CHOL or 2%E or in wild-type littermates (ϩ/ϩ); *, P Ͻ 0.05; ***, P Ͻ 0.001 vs. cholesterol-treated hpg control group. Right, Serum FSH concentrations in wild-type (ϩ/ϩ) adult male C3H mice treated for 12 days with CHOL, 2%E, or 10% 17␤-estradiol implants (10%E); ***, P Ͻ 0.005 vs. cholesteroltreated wild-type control group; arrowhead, assay limit of detection.
third of that for wild-type mice ( Table 2 ). The testosterone treatments produced circulating androgen concentrations within the normal range for adult male mice (Fig. 5) and induced major growth of the seminal vesicles (Fig. 5, bottom) , additional growth of the epididymides (Fig. 5) , and partial induction of spermatogenesis (Fig. 4e) , confirming the bioactivity. However, the supplementary testosterone treatment did not increase testis weight (Fig. 5, top) , or stimulate spermatogenesis beyond that produced by estradiol alone (Fig.  4f) . Testosterone treatment alone did not increase the total volume of Sertoli cell nuclei (Table 2) , and the supplementary testosterone blocked the stimulatory effect of estradiol treatment on total Sertoli cell nuclear volume ( Table 2) .
Discussion
Although induction of spermatogenesis in hpg mice by androgens has been previously reported (19) , our studies demonstrate that administration of estradiol within the normal physiological range (for females) can exert similar effects. The current assay was not sufficiently sensitive to determine normal circulating and intratesticular estradiol concentrations in the male mouse, so we cannot be sure how the levels generated by the 2% implants relate to true physiological values in the male. Nevertheless, the estradiol doses we used are certainly less than those previously reported to alter Sertoli cell replication in the testis when administered to pregnant rodents (26) . The current doses are also far lower than the 15 g per day estradiol benzoate treatment that had been shown to increase the proliferation of type A spermatogonia when delivered to infant rats from 5-11 days of age (27) . Our studies greatly extend these original observations by Kula (27) , who first postulated a stimulatory role for estradiol in spermatogenesis in the rat, because we have demonstrated that: 1) qualitatively, full germ cell development can be induced by estradiol; 2) this can be achieved by concentrations of estradiol that are likely to be in the phys- iological range; and 3) stimulatory actions of estradiol occur in the mouse, as well as in the rat.
Quantitatively, spermatogenesis was reduced, compared with wild-type controls; for example, the total mean seminiferous epithelial volume per testis in estradiol-treated hpg mice was 4-fold less. This may reflect the greatly reduced proliferation, and thus supply, of Sertoli cells in the hpg mouse that have not been exposed to gonadotropin at any stage of development, in contrast to several other models used to study spermatogenesis, in which endocrine support is withdrawn during postnatal life; for example, by hypophysectomy (28) , by destruction of Leydig cells using ethane dimethylsulphonate (29) , or by GnRH immunoneutralization (30) . If hpg mice are treated in the neonatal period with FSH, there is marked proliferation of the Sertoli cell population (31), and subsequent FSH plus androgen treatments are quantitatively more effective in inducing spermatogenesis than in hpg mice that are not treated with FSH during the neonatal period (31) . In fact, the induction of spermatogenesis observed in the estradiol-treated hpg mice was accompanied by significant increase in the total volume of Sertoli cell nuclei and, by inference, in the number of Sertoli cells, though the testes were still markedly deficient in Sertoli cells, when compared with wild-type controls.
Although the estradiol treatments decreased serum FSH concentrations in wild-type mice (as expected), they induced a small (but significant) rise in circulating FSH levels in the male hpg mice. A previous study, in which female hpg mice were treated with sc implants of estradiol benzoate for 5 days, failed to detect an increase in circulating FSH levels, despite the observation of follicular development in the ovary that suggested stimulation by FSH (32) . The increase in FSH in male hpg mice in the current study must reflect a direct pituitary action of estradiol, and it is possible that this paradoxical stimulatory effect of estradiol on the pituitary reflects incomplete masculinization during the neonatal period in male hpg mice, which by their very nature, lack androgen production. This unexpected increase in FSH concentrations in hpg mice treated with estradiol provides one possible explanation for the induction of spermatogenesis. A large body of evidence indicates that FSH and testosterone support the completion of meiosis and spermiogenesis via actions on Sertoli cells (see Ref. 33 for review), but it is controversial as to whether FSH alone can initiate spermatogenesis in the absence of androgens. Could the low levels FIG. 5. Exp III. From top to bottom, Paired testes weights, serum testosterone concentrations, serum FSH concentrations, paired epididymides weights, and paired seminal vesicle weights in hpg mice treated for 70 days with cholesterol implants (chol), 2% E or 10% 17␤-estradiol implants (2% E or 10% E) and in untreated age-matched wild-type littermates (ϩ/ϩ). cholϩT and 2%EϩT groups also received testosterone implants for the latter 35 days of the experiment. Values are group mean Ϯ SE. Group size is indicated at the bottom; except for serum FSH values, where group sizes are n ϭ 3, or n ϭ 2 where error bars have been replaced with the values for individual mice. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001 vs. cholesteroltreated control group. Note that the additional testosterone treatment produced physiological concentrations of testosterone in the circulation and increased growth of the epididymides and seminal vesicles, but did not induce further testis growth, compared with the hpg mice only receiving estradiol treatments.
of FSH induced by the estradiol treatments in the current study be sufficient to drive spermatogenesis? One study of the hpg mouse (34) concluded that FSH alone was not sufficient to complete spermatogenesis, in that FSH treatment given to weanling (day-21) mice increased proliferation of spermatogonia and primary spermatocytes, but condensed (i.e. fully elongated) spermatids were not formed by 70 days of age. However, important differences between that study and the present observations should be noted. That study (34) used recombinant human FSH rather than murine FSH, the treatment was given once daily rather than a continual release that would be predicted in the current estradiol treatment, and the treatment was only continued for 49 days; FSH may have been increased for all 70 days of the estradiol treatment in the current study. Moreover, inspection of the photomicrographs in the previous study (34) does indicate the presence of round and early elongating spermatids after FSH treatment alone. Furthermore, a quantitative assessment of germ cell development was reported, revealing that approximately one million round spermatids per testis were formed after FSH treatment, whereas these germ cells were totally absent in age-matched, untreated hpg mice (34) . The issue of the role of FSH in initiation of spermatogenesis is confounded by the possibility that FSH might indirectly promote androgen production by Leydig cells. Treatment of hpg mice, at an adult age, with purified ovine FSH stimulated the development of round spermatids and increased the androgenic capacity of the testes, as determined in vitro (18) , though no effects of 10 days of FSH treatment on serum testosterone or testicular content of androgen occurred (18) . Likewise, in the current study, circulating testosterone concentrations remained below the limit of detection in the estradiol-treated hpg mice with increased FSH levels. The slight (but significant) increase in the weight of the seminal vesicles in the estradiol-treated hpg mice could indicate small rises in circulating androgen that our assay was unable to detect. However, two previous studies of the effects of ovine FSH (18) or human recombinant FSH (34) in hpg mice failed to detect any increase in intratesticular testosterone levels; thus, there is little reason to believe that the small increases in FSH concentrations induced by estradiol in the current study would have raised intratesticular testosterone to a level detectable by immunoassay or ELISA. An unequivocal test of any role for FSH and androgens in estradiol-induced spermatogenesis may best be obtained by introducing mutations of the FSH ␤-subunit gene or receptor (35, 36) or androgen receptor (should such mice be produced) into the hpg line, and then examining whether the stimulatory effects of estradiol on spermatogenesis are abolished.
Even if FSH alone is sufficient to initiate spermatogenesis, it is certainly not absolutely necessary, as revealed by the partial fertility in male mice genetically modified to be deficient in FSH ␤-subunit production (35) or lacking the FSH receptor (36) . An alternative (or perhaps additional) explanation of the current observations is that there are effects of estrogen directly on the germ cell line. Whereas ER␣ is only expressed in Leydig cells, an immunocytochemical study in the rat has revealed ER␤ in Sertoli cells and in germ cells (9) , though the abundance of ER␤ immunoreactivity in spermatocytes decreased after the pachytene phase of meiotic maturation (9) . Consistent with these findings in the rat, a recent in situ hybridization study has demonstrated ER␤ messenger RNA in both Sertoli cells and germ cells in adult Cynomolgus monkeys (37) . Given the identification of aromatase in germ cells of the mouse testis (38) , it is possible that some of the actions previously ascribed to androgens acting on Sertoli cells are, in fact, mediated via aromatization to estradiol acting on germ cells directly, and that this is what the current experimental treatment is mimicking. Estrogen synthesis has been demonstrated in the fetal rat testis (39, 40) ; so, it is possible that because the testis in the hpg mouse is essentially neonatal throughout life, then such testes remain sensitive to the effects of estradiol. It was recently reported (41) that estradiol could induce proliferation of isolated rat fetal gonocytes in vitro, so there is a precedent for estrogenic actions on the germ cell line. Although that study (41) used doses of estradiol in the micromolar range to induce proliferation of gonocytes, this may not necessarily be supraphysiological, because fetal rat Sertoli cells would seem to secrete high levels of this steroid (39, 40) . There is also in vitro evidence for estrogenic actions on Sertoli cells themselves, in that physiological doses of estradiol increase inhibin B production by Sertoli cell cultures derived from 18-day-old rats (42) .
The slight growth of the seminal vesicles in the estradioltreated hpg mice could also reflect actions of estradiol, in the male reproductive tract, mediated via androgen receptors. Although we cannot unequivocally rule out the possibility that the effects of estradiol on spermatogenesis are mediated via such a pathway, we consider it unlikely. To date, the evidence for such cross-talk between estrogen and androgen receptors is based entirely on in vitro studies employing a prostate cancer cell line (43) , and using supraphysiological concentrations of estradiol (43) . Support for a physiological role of estrogen in spermatogenesis comes from the recent observations that there is a progressive long-term deterioration in spermatogenesis in genetically modified mice lacking aromatase (44, 45) . Although young (2-3 month) male ER␤ knockout mice are reported to be fertile (46), it is not known whether there is a subsequent impairment of spermatogenesis with increasing age, as reported for 1-yr-old male mice lacking aromatase (45) . The widespread expression of aromatase, ER␣, and ER␤ in different compartments of the testis points to a physiological role for estrogen in many aspects of testicular function. The development of infertility in ER␣ knockout mice may be partly attributed to an impairment of fluid reabsorption from the testicular efferent ducts; but other actions of estrogen in the testis are beginning to emerge [for example, on the proliferation of Sertoli cells early in life (26) and on the expression of steroidogenic factor 1 (13)].
In conclusion, the current observations of induction of spermatogenesis in hpg mice may reflect indirect actions via stimulation of FSH secretion, or direct effects within the testis on the development of the germ cell line, or a combination of these two processes. Further studies are justified to resolve this and to determine whether the unusual reproductive development (possible lack of neonatal androgenization) in this mutant line contribute to the observed effects of estrogen. Notwithstanding these caveats, these studies identify potentially important actions of estrogen on reproductive function in the male that might be mimicked or antagonized by environmental chemicals with estrogenic properties.
